New indication for Syntara lead asset SNT-5505 as German MDS study group awarded A$2.5m grant to conduct phase 2 blood cancer trial Read More »
Syntara CEO Gary Phillips Speaks with JustStocks Video As Phase 2 Blood Cancer Trial Fully Recruits Read More »